The S100A8/A9 heterodimer, the dominant form in serum, has been observed in patients with SLE as well as in those with cardiovascular disease in SLE and active lupus nephritis and can predict responses to treatment of SLE (6, 11, 13, 30, 31). This evidence concerns the gene IGKV1D-22 and systemic lupus erythematosus.